CG Oncology, Inc. Common stock (CGON) Research

CG Oncology Inc. is a biotechnology company in the clinical development stage, committed to advancing and bringing to market an innovative, bladder-sparing core treatment for individuals diagnosed with bladder cancer. Their principal drug candidate, cretostimogene, is presently undergoing clinical evaluation. Its initial focus is on providing a therapeutic option for patients suffering from high-risk Non-Muscle Invasive Bladder Cancer who have not responded to Bacillus Calmette Guerin (BCG) therapy, which represents the established standard of care for this particular severe form of NMIBC.

Market snapshot

Symbol
CGON
Price
$61.08
Day change
+1.08%
Market cap
$5.4B
P/E ratio
-27.64x
52-week range
23.65-75.5
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$82.57

Recent news

  • CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings

    CG Oncology (NASDAQ:CGON) reported mixed results for the first quarter on Friday.

Peer companies

  • Ascentage Pharma Group International (AAPG)
  • Apogee Therapeutics, Inc. (APGE)
  • Celcuity Inc. (CELC)
  • Centessa Pharmaceuticals plc (CNTA)
  • Disc Medicine, Inc. (IRON)
  • Legend Biotech Corporation (LEGN)
  • Ultragenyx Pharmaceutical Inc. (RARE)
  • Tarsus Pharmaceuticals, Inc. (TARS)

Recent insider activity

  • Mulay James — M-Exempt (1310 shares) on 2026-06-15
  • Mulay James — M-Exempt (1310 shares) on 2026-06-15
  • Mulay James — M-Exempt (654 shares) on 2026-06-15
  • Mulay James — S-Sale (1310 shares) on 2026-06-15
  • Mulay James — M-Exempt (654 shares) on 2026-06-15

Open CG Oncology, Inc. Common stock (CGON) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.